AIM Rule 26 Information

RNS Number:2682C
EiRx Therapeutics PLC
16 August 2007

                     EIRX THERAPEUTICS PLC (the "Company")

               Disclosure of information required by AIM rule 26

Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company
developing targeted therapies for the treatment of cancer, confirms that the
information required by AIM Rule 26 for Companies (company information
disclosure) is available on the Investors section of the Company's website at
www.eirx.com/investors.html.

EiRx Therapeutics plc
Colin Telfer PhD, Chief Executive Officer
+353 (0)21 432 0847

Grant Thornton Corporate Finance
Philip Secrett / Colin Aaronson
+44 (0)20 7383 5100

Buchanan Communications
Tim Anderson / Mary-Jane Johnson
+44 (0)20 7466 5000

16th August 2007


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCSFWFIMSWSELA

Eirx Therapeutics (LSE:ERX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024